Tris(8-quinolinolato)gallium(III) (KP46) and tris(maltolato)gallium(III) (GaM) are promising orally active antitumor metallodrugs currently undergoing clinical trials. Their interaction with human serum albumin (HSA) and transferrin (Tf) was studied in detail in aqueous solution by the combination of various methods such as spectrofluorometry, UV-vis spectrophotometry, 1H and saturation transfer difference NMR spectroscopy, and ultrafiltration-UV-vis spectrophotometry. Binding data were evaluated quantitatively. Tf was found to replace the original ligand much less efficiently in KP46 than in GaM, whereas a significant noncovalent binding of KP46 with HSA (log K' = 4.04) retaining the coordination environment around gallium(III) was found. The interaction between HSA and KP46 was also confirmed by protein-complex modeling calculations. On the basis of the conditional stability constants, the distribution of gallium(III) in serum was computed and compared for these metallodrugs under physiological conditions, and revealed the prominent role of HSA in the case of KP46 and that of Tf for GaM.
|Autori interni:||TUCCINARDI, TIZIANO|
|Autori:||Enyedy EA; Dömötör O; Bali K; Hetényi A; Tuccinardi T; Keppler BK.|
|Titolo:||Interaction of the anticancer gallium(III) complexes of 8-hydroxyquinoline and maltol with human serum proteins.|
|Anno del prodotto:||2015|
|Digital Object Identifier (DOI):||10.1007/s00775-014-1211-9|
|Appare nelle tipologie:||1.1 Articolo in rivista|